Novartis company profile
Company profile
Novartis has 75,267 employees and is headquartered in Basel, Switzerland.
With 75,267 employees, the Swiss pharmaceutical group researches, develops, manufactures and sells prescription medicines in Switzerland and across the world. Its portfolio includes Entresto for chronic heart failure, Cosentyx for psoriasis and spondylitis, Kisqali, an oral kinase inhibitor, Pluvicto for advanced prostate cancer and Zolgensma for spinal muscular atrophy. Leqvio, which lowers LDL cholesterol, is developed under a license and collaboration agreement with Alnylam Pharmaceuticals. Its research and sales focus on heart and kidney disease, metabolic conditions, immunology, neuroscience, oncology and hematology.
In the fiscal year ended December 2025, revenue reached 56.7 billion US dollars, up 9.6% from the previous year, and net income was 14.0 billion US dollars. By region, the United States accounted for 42.8% of revenue, other countries for 39.8%, China for 7.7% and Germany for 7.2%. The company is headquartered in Basel, Switzerland, and its shares also trade on the New York Stock Exchange.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Switzerland
- Headquarters
- Lichtstrasse 35, 4056, Basel
- Employees
- 75,267
- Chief executive
- Vasant Narasimhan
- Founded
- 1996
- Fiscal year
- January - December
- Listing
- NOVN · SIX
- Indices
- SMI
- Currency
- CHF
- ISIN
- CH0012005267
- Website
- novartis.com
Novartis and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| NovartisNOVN | Switzerland | $301.99B | 75,267 | 34.0% | 32.1 |
| AstraZenecaAZN | United Kingdom | $286.82B | 96,100 | 25.8% | 26.5 |
| Roche HoldingROP | Switzerland | $387.55B | 103,249 | 33.1% | 26.6 |
| Novo NordiskNOVO.B | Denmark | $181.48B | 68,794 | 50.8% | 10.9 |
| SanofiSAN | France | $116.24B | 74,846 | 22.3% | 25.3 |
| GSKGSK | United Kingdom | $101.36B | 66,841 | 30.5% | 17.9 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
